There's no sense in delaying Social Security past age 70
By the time many people reach age 70, they’ve already been collecting Social Security for years. But if you’re nearing your 70th birthday or recently turned 70 and haven’t started benefits yet, there’s a key Social Security rule you need to know about.
There’s no sense in delaying Social Security past age 70
The earliest age you can claim Social Security is 62.
» Read more about: There's no sense in delaying Social Security past age 70 »
Read MoreVanguard Total Stock Market Index Fund Admiral Shares (VTSAX): What Investors Should Know
© Nikada / E+ via Getty Images
A 0.04% expense ratio is not a typo. Vanguard Total Stock Market Index Fund Admiral Shares (NASDAQ:VTSAX) charges 0.04% a year to own effectively the entire U.S. stock market. On a $100,000 balance,
Is It Too Late to Buy Micron Stock After Its 981% Surge?
Key Points
-
Micron’s margin growth rate is slowing down, suggesting that the red-hot earnings growth it has been delivering may not be sustainable.
-
However, the memory market’s dynamics suggest otherwise, as strong shipment volumes driven by pent-up demand for smartphones and PCs will be a tailwind for Micron.
» Read more about: Is It Too Late to Buy Micron Stock After Its 981% Surge? »
Read MoreUS-Canada trade war escalates as Trump threatens tariff hike on vehicles
In Portland, Oregon, Mike Roach and Kim Osgood, owners of Paloma Clothing say the price of one of their best-selling items – specially designed pillows made in Canada – could shoot up by around 50% to $90. For now, they are holding out on keeping the prices steady, hoping that the “tariff problem”
» Read more about: US-Canada trade war escalates as Trump threatens tariff hike on vehicles »
Read MoreNVIDIA Q2 results | Share price up 11% YTD; is it a stock to buy after earnings and amid AI boom?
NVIDIA’s second-quarter (Q2) results exceeded expectations, and its revenue guidance for the next financial year beat estimates. However, none of this moved the market. The stock declined 1.59% to end at $209.66 on Nasdaq on 26 August.
The chipmaker’s revenue for the July quarter more than doubled to $96.2 billion,
The Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
Will This ETF 2x Before Year End?
In recent months, some of the most sophisticated investors on Wall Street have made a bold move by pouring hundreds of millions into BlackRock’s iShares Bitcoin Trust (IBIT).
This isn’t just a passing trade but a conviction bet that Bitcoin’s best days may still be ahead and while still trading under $100,000 per coin,
» Read more about: Will This ETF 2x Before Year End? »
Read MoreThe Spotlight
Why This Beverage Giant Can’t Be Toppled
A famous book on business was titled Barbarians at the Gate, documenting the leveraged buyout of RJR Nabisco. If nothing else, it highlights how just the sniff of an opportunity to make money can drive money seekers to make wild decisions.
Some giant businesses have been on the receiving end of similar threats to their solvency as invaders attempt to take their share.
» Read more about: Why This Beverage Giant Can’t Be Toppled »